Drugs Made InDMAA.OValuation Analysis

As of Oct 16, 2026, Drugs Made In (DMAA.O) trades at a P/E of 43.30x, P/B of 1.92x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 32nd percentile over the trailing 10Y window (vs. 32nd percentile over 3Y); P/B sits at the 100th percentile over the trailing 10Y window (vs. 100th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/E ranks at the 82nd percentile within its industry and the 82nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 67.6 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Drugs Made In operates in the Finance, Insurance, And Real Estate sector. Data refreshes weekly and is for reference only, not investment advice.